phosphate Inhibitors
1 drugsAbout phosphate
Phosphate is an inorganic chemical vital for numerous biological processes. While its precise mechanisms in disease are still being researched, it has emerged as a target of interest in drug development.
Currently, there is no genetic evidence directly linking phosphate to specific diseases, highlighting an area for future research. Modulating phosphate levels could unlock new treatment strategies for a range of conditions.
AURYXIA is the only FDA-approved drug targeting phosphate, indicated for three conditions and developed by KERYX BIOPHARMS. It is a small molecule, representing the sole modality in this therapeutic area.
Top phosphate Drugs
KERYX BIOPHARMS is the only company with an approved drug targeting phosphate.
Low competition suggests an opportunity for new entrants, but also indicates potential challenges in the therapeutic area.
phosphate Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets phosphate, using small molecule modality.
Exploring alternative modalities like antibodies or biologics could provide a competitive advantage.
phosphate Clinical Trials 24 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on phosphate. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 | 100% |
| Phase 2 | 3 | 2 | 0 | 1 | 100% |
| Phase 3 | 14 | 11 | 1 | 1 | 92% |
| Phase 4 | 6 | 4 | 1 | 1 | 80% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
phosphate Drug Approval Timeline (2014 - 2014)
The first and most recent drug approval for a phosphate target was AURYXIA in 2014.
The lack of recent approvals suggests a potentially saturated market or challenges in developing new phosphate-targeting drugs.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 13 (4 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on phosphate. A trial counts if an approved drug acting on phosphate is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.